)
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Pneumococcal vaccines address infections caused by pneumococcal bacteria, including pneumonia, meningitis, and blood infections, collectively known as invasive pneumococcal disease
Platform includes 'free for life', CBSE-based resources to help educators meet evolving needs of education
The collaboration aims to tackle AMR in India by focusing on tier 2 and tier 3 cities, bridging the gap between awareness and action, and ensuring sustainable AMR interventions
Collaboration comes days after UCL signed agreement with IISc Bengaluru on clinical education
Report suggests the sector still faces sustainability issues due to profit crunch, expanding competition from large chains
Jump in numbers comes as north Indian cities record AQI in excess of 350, Mumbai crosses 120
The company is seeing a huge growth opportunity in English language learning, assessment and testing, and higher education
The company also reported a 14.6 per cent rise in revenues in the European market to Rs 687.4 crore, while recording a 1.2 per cent revenue drop in the North America market
Each PAIR network will consist of one hub and up to seven spoke institutions
The company's ARPOB per day rose to Rs 62,140 in Q2 FY25, a marginal growth of 1.9 per cent Y-o-Y compared to Rs 61,003 reported for the same period last year
Two newly inaugurated units will manufacture important molecules used in several common antibiotics
The growth is attributed to strong performances across domestic and international formulations, and double-digit growth in the consumer wellness business
The value growth comes at a time when the IPM has registered a negative volume growth of 1.8 per cent
This initial outlay of Rs 500 crore will be for three years, up to financial year 2026-27 (FY27), according to a government communication
The company's revenue from operations rose to Rs 1,988 crore in Q2 FY25, a 12.3 per cent Y-o-Y increase from Rs 1,770 crore reported in Q2 FY24
The growth is attributed to higher occupancy rates and an increase in revenue per bed during the September quarter
JB Pharma is on track to deliver strong results in the second half of financial year 2024-25
Rs 3,600 crore outlay outlined for the scheme till FY31
"The hospital is expected to commence operations in around four years, subject to necessary statutory and customary approvals"
The company stated it has a strong order book for the remaining quarters of this financial year